FDA reduces Lunesta starting dose

Share this article:

The Food and Drug Administration is requiring Sunovion to reduce the recommended starting dose for sleep drug Lunesta (eszopilcone) from 2mg to 1mg for both men and women.

The regulator announced Thursday that patients may end up using higher—as in 2mg or 3mg—doses if needed, but they should begin with 1mg because “higher doses are more likely to result in next-day impairment of driving and other activities that require full alertness.”

The FDA said the study of 91 patients found “severe next-morning psychomotor and memory impairment” that could impair driving skills, memory and coordination up to 11 hours after ingestion.

The FDA's notice adds that “patients were often unaware they were impaired.”

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters